Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Mar 1;111(3):331-334.
doi: 10.1093/jnci/djy182.

Risk-Reducing Oophorectomy and Breast Cancer Risk Across the Spectrum of Familial Risk

Affiliations
Free PMC article

Risk-Reducing Oophorectomy and Breast Cancer Risk Across the Spectrum of Familial Risk

Mary Beth Terry et al. J Natl Cancer Inst. .
Free PMC article

Abstract

There remains debate about whether risk-reducing salpingo-oophorectomy (RRSO), which reduces ovarian cancer risk, also reduces breast cancer risk. We examined the association between RRSO and breast cancer risk using a prospective cohort of 17 917 women unaffected with breast cancer at baseline (7.2% known carriers of BRCA1 or BRCA2 mutations). During a median follow-up of 10.7 years, 1046 women were diagnosed with incident breast cancer. Modeling RRSO as a time-varying exposure, there was no association with breast cancer risk overall (hazard ratio [HR] = 1.04, 95% confidence interval [CI] = 0.87 to 1.24) or by tertiles of predicted absolute risk based on family history (HR = 0.68, 95% CI = 0.32 to 1.47, HR = 0.94, 95% CI = 0.70 to 1.26, and HR = 1.10, 95% CI = 0.88 to 1.39, for lowest, middle, and highest tertile of risk, respectively) or for BRCA1 and BRCA2 mutation carriers when examined separately. There was also no association after accounting for hormone therapy use after RRSO. These findings suggest that RRSO should not be considered efficacious for reducing breast cancer risk.

Figures

Figure 1.
Figure 1.
Model comparison for women who were unaffected at baseline, ProF-SC. Adjusted for age at baseline, race/ethnicity, study center, and Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) score. Time-dependent models count individuals as unexposed before risk-reducing salpingo-oophorectomy (RRSO) and exposed after RRSO; non-time-dependent models treat RRSO as a fixed effect. A) summarizes the results from models treating RRSO as both a fixed and time varying exposure for the overall cohort stratified by tertile of predicted absolute risk of breast cancer as estimated by BOADICEA. B) summarizes results from models treating RRSO as both a fixed and time varying exposure for BRCA1 mutation carriers, BRCA2 mutation carriers, and non-carriers. C) presents time-dependent models for non-carriers stratified by age at RRSO or by age at hormone replacement therapy (HRT) use after RRSO. D) presents time-dependent models for women in the upper tertile of absolute risk of breast cancer as estimated by BOADICEA, stratified by age at RRSO or by age at hormone replacement therapy (HRT) use after RRSO. All panels present models starting follow-up time at at age 25 years or at baseline age.

Similar articles

See all similar articles

Cited by 5 articles

  • Preventing Breast Cancer in High-Risk Women: Is There Still a Role for Oophorectomy?
    Norquist BM, Swisher EM, Yung RL. Norquist BM, et al. JNCI Cancer Spectr. 2019 Oct 4;4(1):pkz076. doi: 10.1093/jncics/pkz076. eCollection 2020 Feb. JNCI Cancer Spectr. 2019. PMID: 32337493 Free PMC article. No abstract available.
  • Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers.
    Mavaddat N, Antoniou AC, Mooij TM, Hooning MJ, Heemskerk-Gerritsen BA; GENEPSO, Noguès C, Gauthier-Villars M, Caron O, Gesta P, Pujol P, Lortholary A; EMBRACE, Barrowdale D, Frost D, Evans DG, Izatt L, Adlard J, Eeles R, Brewer C, Tischkowitz M, Henderson A, Cook J, Eccles D; HEBON, van Engelen K, Mourits MJE, Ausems MGEM, Koppert LB, Hopper JL, John EM, Chung WK, Andrulis IL, Daly MB, Buys SS; kConFab Investigators, Benitez J, Caldes T, Jakubowska A, Simard J, Singer CF, Tan Y, Olah E, Navratilova M, Foretova L, Gerdes AM, Roos-Blom MJ, Van Leeuwen FE, Arver B, Olsson H, Schmutzler RK, Engel C, Kast K, Phillips KA, Terry MB, Milne RL, Goldgar DE, Rookus MA, Andrieu N, Easton DF; IBCCS; kConFab; BCFR. Mavaddat N, et al. Breast Cancer Res. 2020 Jan 16;22(1):8. doi: 10.1186/s13058-020-1247-4. Breast Cancer Res. 2020. PMID: 31948486 Free PMC article.
  • Accuracy of Risk Estimates from the iPrevent Breast Cancer Risk Assessment and Management Tool.
    Phillips KA, Liao Y, Milne RL, MacInnis RJ, Collins IM, Buchsbaum R, Weideman PC, Bickerstaffe A, Nesci S, Chung WK, Southey MC, Knight JA, Whittemore AS, Dite GS, Goldgar D, Giles GG, Glendon G, Cuzick J, Antoniou AC, Andrulis IL, John EM, Daly MB, Buys SS, Hopper JL, Terry MB; kConFab Investigators. Phillips KA, et al. Version 2. JNCI Cancer Spectr. 2019 Sep 19;3(4):pkz066. doi: 10.1093/jncics/pkz066. eCollection 2019 Dec. JNCI Cancer Spectr. 2019. PMID: 31853515 Free PMC article.
  • Surgically Induced Menopause-A Practical Review of Literature.
    Secoșan C, Balint O, Pirtea L, Grigoraș D, Bălulescu L, Ilina R. Secoșan C, et al. Medicina (Kaunas). 2019 Aug 14;55(8):482. doi: 10.3390/medicina55080482. Medicina (Kaunas). 2019. PMID: 31416275 Free PMC article. Review.
  • BRCA Mutations and Breast Cancer Prevention.
    Kotsopoulos J. Kotsopoulos J. Cancers (Basel). 2018 Dec 19;10(12):524. doi: 10.3390/cancers10120524. Cancers (Basel). 2018. PMID: 30572612 Free PMC article. Review.

References

    1. Domchek SM, Friebel TM, Singer CF., et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304(9):967–975. - PMC - PubMed
    1. Domchek SM, Stopfer JE, Rebbeck TR. Bilateral risk-reducing oophorectomy in BRCA1 and BRCA2 mutation carriers. J Natl Compr Canc Netw. 2006;4(2):177–182. - PubMed
    1. Eisen A, Lubinski J, Klijn J., et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol. 2005;23(30):7491–7496. - PubMed
    1. Kauff ND, Domchek SM, Friebel TM., et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol. 2008;26(8):1331–1337. - PMC - PubMed
    1. Heemskerk-Gerritsen BA, Seynaeve C, van Asperen CJ., et al. Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction. J Natl Cancer Inst. 2015;107(5):djv033. - PubMed

Publication types

Feedback